ATC Group: R05CB01 Acetylcysteine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R05CB01 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R05 Cough and cold preparations
3 R05C Expectorants, excl. combinations with cough suppressants
4 R05CB Mucolytics
5 R05CB01 Acetylcysteine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.5 g
RESPIR - Respiratory (Inhalation) (solution) 1.6 g

Active ingredients in R05CB01

Active Ingredient Description
Acetylcysteine

Acetylcysteine is N-acetyl derivative of cysteine. Used as a mucolytic agent to reduce the viscosity of mucous secretions.

Related product monographs

Title Information Source Document Type  
NACSYS Effervescent tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TREBON Powder for oral solution Health Products Regulatory Authority (IE) MPI, EU: SmPC
TUSSMUCO Effervescent tablet Health Products Regulatory Authority (ZA) MPI, Generic

Medicines in this ATC group

Croatia (HR)

Cyprus (CY)

Germany (DE)

Ireland (IE)

Israel (IL)

Lithuania (LT)

Malta (MT)

Netherlands (NL)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.